ClinicalTrials.gg

Program

HLX13

A development code.

Its studies are mostly in Carcinoma, Hepatocellular, led by Fosun Pharma.

Furthest: phase 3, since Feb 18, 20253 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma33 open or runningphase 3since Feb 18, 2025Nov 28, 2023Dec 2026phase 1 · NCT07176650

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 28, 2023First study: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12First studyNCT06159101 · 304 planned · China
  2. Feb 18, 2025Phase 3 study in Carcinoma, HepatocellularNCT06841185 · 656 planned
  3. Sep 1, 2025Phase 1 study in Carcinoma, HepatocellularNCT07176650 · 246 planned · United States, China

Ahead

  1. Dec 2026Primary completion: phase 1 study in Carcinoma, HepatocellularNCT07176650
  2. Jun 6, 2027Primary completion: phase 3 study in Carcinoma, HepatocellularNCT06841185

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07176650Carcinoma, Hepatocellular · United States, China1RecruitingDec 2026246
NCT06841185Carcinoma, Hepatocellular3Not yet recruitingJun 6, 2027656
NCT06159101Diabetes Mellitus, Insulin-Dependent, 12 · China1RecruitingMay 28, 2024304

How it is read

Names in the registry

  • “HLX13”, 3 entries

Codes read as this program: HLX13.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
HLX13 (Fosun Pharma): development program | ClinicalTrials.gg